Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells

Kim,Dong Hwan; Kim,Min Jeong; Sung,Bokyung; Suh,Hongsuk; Jung,Jee H.; Chung,Hae Young; Kim,Nam Deuk

doi:10.3892/or.2016.5219

Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells

Authors:
- Dong Hwan Kim
- Min Jeong Kim
- Bokyung Sung
- Hongsuk Suh
- Jee H. Jung
- Hae Young Chung
- Nam Deuk Kim
View Affiliations

Affiliations: Department of Pharmacy, Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan 46241, Republic of Korea, Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan 46241, Republic of Korea
Published online on: November 7, 2016 https://doi.org/10.3892/or.2016.5219
Pages: 281-288

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol, a polyphenolic compound, is a naturally occurring phytochemical and is found in a variety of plants, including grapes, berries and peanuts. It has gained much attention for its potential anticancer activity against various types of human cancer. However, the usefulness of resveratrol as a chemotherapeutic agent is limited by its photosensitivity and metabolic instability. In this study the effects of a synthetic analogue of resveratrol, HS-1793, on the proliferation and apoptotic cell death were investigated using HCT116 human colon cancer cells. Although this compound has been reported to have anticancer activities in several human cancer cell lines, the therapeutic effects of HS-1793 on human colon cancer and its mechanisms of action have not been extensively studied. HS-1793 inhibited cell growth and induced apoptotic cell death in a concentration-dependent fashion. Induction of apoptosis was determined by morphological changes, cleavage of poly(ADP-ribose) polymerase, alteration of Bax/Bcl-2 expression ratio, and caspase activations. Flow cytometric analysis revealed that HS-1793 induced G2/M arrest in the cell cycle progression in HCT116 cells. Furthermore, HS-1793 showed more potent anticancer effects in several aspects than resveratrol in HCT116 cells. In addition, HS-1793 suppressed Akt and the phosphatidylinositol-3 kinase/Akt inhibitor LY294002 was found to enhance its induction of apoptosis. Thus, these findings suggest that HS-1793 have potential as a candidate chemotherapeutic agent against human colon cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH and Lee KH: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 47:127–141. 2015. View Article : Google Scholar : PubMed/NCBI
3	Shin A, Kim KZ, Jung KW, Park S, Won YJ, Kim J, Kim DY and Oh JH: Increasing trend of colorectal cancer incidence in Korea, 1999–2009. Cancer Res Treat. 44:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
4	Li YH, Niu YB, Sun Y, Zhang F, Liu CX, Fan L and Mei QB: Role of phytochemicals in colorectal cancer prevention. World J Gastroenterol. 21:9262–9272. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC and Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61:7456–7463. 2001.PubMed/NCBI
6	Schneider Y, Duranton B, Gossé F, Schleiffer R, Seiler N and Raul F: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer. 39:102–107. 2001. View Article : Google Scholar : PubMed/NCBI
7	Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y and Imamura M: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 23:1531–1536. 2002. View Article : Google Scholar : PubMed/NCBI
8	Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP and Gescher AJ: Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans-3,4,5,4-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min⁺) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer. 115:194–201. 2005. View Article : Google Scholar : PubMed/NCBI
9	Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 9:1474–1476. 2003. View Article : Google Scholar : PubMed/NCBI
10	Chen Y, Tseng SH, Lai HS and Chen WJ: Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery. 136:57–66. 2004. View Article : Google Scholar : PubMed/NCBI
11	Pan MH, Gao JH, Lai CS, Wang YJ, Chen WM, Lo CY, Wang M, Dushenkov S and Ho CT: Antitumor activity of 3,5,4-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog. 47:184–196. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chen JC, Chen Y, Lin JH, Wu JM and Tseng SH: Resveratrol suppresses angiogenesis in gliomas: Evaluation by color Doppler ultrasound. Anticancer Res. 26:1237–1245. 2006.PubMed/NCBI
13	Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argilés JM and López-Soriano FJ: Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 245:144–148. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kosmeder JW II, Pezzuto JM, Pezzuto JM and Bhat KP: Biological effects of resveratrol. Antioxid Redox Signal. 3:1041–1064. 2001. View Article : Google Scholar : PubMed/NCBI
15	Harikumar KB and Aggarwal BB: Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle. 7:1020–1035. 2008. View Article : Google Scholar : PubMed/NCBI
16	Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI
17	Cai YJ, Wei QY, Fang JG, Yang L, Liu ZL, Wyche JH and Han Z: The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res. 24:999–1002. 2004.PubMed/NCBI
18	Szekeres T, Fritzer-Szekeres M, Saiko P and Jäger W: Resveratrol and resveratrol analogues - structure-activity relationship. Pharm Res. 27:1042–1048. 2010. View Article : Google Scholar : PubMed/NCBI
19	Song S, Lee H, Jin Y, Ha YM, Bae S, Chung HY and Suh H: Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 17:461–464. 2007. View Article : Google Scholar : PubMed/NCBI
20	Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo KS, Song S, Suh H, Kwon TK, Park BS and Yoo YH: A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol. 35:1353–1360. 2009.PubMed/NCBI
21	Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009. View Article : Google Scholar : PubMed/NCBI
22	Um HJ, Bae JH, Park JW, Suh H, Jeong NY, Yoo YH and Kwon TK: Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. Int J Oncol. 36:1007–1013. 2010.PubMed/NCBI
23	Kim JA, Kim DH, Hossain MA, Kim MY, Sung B, Yoon JH, Suh H, Jeong TC, Chung HY and Kim ND: HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. Int J Oncol. 44:473–480. 2014.PubMed/NCBI
24	Kim DH, Hossain MA, Kim MY, Kim JA, Yoon JH, Suh HS, Kim GY, Choi YH, Chung HY and Kim ND: A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells. Int J Oncol. 43:1915–1924. 2013.PubMed/NCBI
25	Wang C and Youle RJ: The role of mitochondria in apoptosis. Annu Rev Genet. 43:95–118. 2009. View Article : Google Scholar : PubMed/NCBI
26	Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
27	Perry JA and Kornbluth S: Cdc25 and Wee1: Analogous opposites? Cell Div. 2:122007. View Article : Google Scholar : PubMed/NCBI
28	Liu B, Zhou Z, Zhou W, Liu J, Zhang Q, Xia J, Liu J, Chen N, Li M and Zhu R: Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/S phase cell cycle arrest and apoptosis through caspase/cyclin CDK pathways. Mol Med Rep. 10:1697–1702. 2014.PubMed/NCBI
29	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
30	Jeong NY, Yoon YG, Rho JH, Lee JS, Lee SY, Yoo KS, Song S, Suh H, Choi YH and Yoo YH: The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol. 38:1597–1604. 2011.PubMed/NCBI
31	Jeong SH, Song IS, Kim HK, Lee SR, Song S, Suh H, Yoon YG, Yoo YH, Kim N, Rhee BD, et al: An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression. Mol Cells. 34:357–365. 2012. View Article : Google Scholar : PubMed/NCBI
32	Kim HJ, Yang KM, Park YS, Choi YJ, Yun JH, Son CH, Suh HS, Jeong MH and Jo WS: The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Int J Oncol. 41:1628–1634. 2012.PubMed/NCBI
33	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
34	Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C and Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene. 9:71–79. 1994.PubMed/NCBI
35	Malinowsky K, Nitsche U, Janssen KP, Bader FG, Späth C, Drecoll E, Keller G, Höfler H, Slotta-Huspenina J and Becker KF: Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer. Br J Cancer. 110:2081–2089. 2014. View Article : Google Scholar : PubMed/NCBI
36	Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH and Evers BM: Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA. 105:20315–20320. 2008. View Article : Google Scholar : PubMed/NCBI
37	Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI